Jaykay Enterprises retains Rs 22.32 crore Neumesh balance unprovided
Key highlights
- Jaykay Enterprises disclosed Rs 22.32 crore of total exposure to Neumesh Labs at September 30, 2026.
- Neumesh Labs reported negative net worth of Rs 35.3411 crore and a Rs 36.3141 crore current-liability excess.
- Jaykay Enterprises recognised no impairment or diminution provision on the Neumesh balance for the September 2026 quarter or half year.
- Jaykay Enterprises reported September-quarter standalone net profit of Rs 49.42 lakh, versus Rs 1.0074 crore a year earlier.
powered by IRIS

Jaykay Enterprises Limited retained Rs 22.32 crore of exposure to subsidiary Neumesh Labs Private Limited at September 30, 2026 without recognising a credit-impairment or value-diminution provision, despite the subsidiary reporting negative net worth of Rs 35.3411 crore, paused commercial operations and no property, plant and equipment.
Know Jaykay Enterprises inside out
Results, valuation, peers and who's buying, in one view.
Why did Jaykay Enterprises retain the Neumesh carrying value?
Jaykay Enterprises retained the carrying value because management considers its investment, loans and interest receivable recoverable through proposed recovery strategies. The September 30, 2026 results say Neumesh Labs had temporarily paused commercial operations but was formulating a digital-services business plan intended to revive operations. Management therefore did not recognise a provision in either the September 2026 quarter or the six months ended September 30, 2026.
The statutory auditor highlighted this accounting treatment in an emphasis-of-matter paragraph in its limited-review report dated November 13, 2026. The auditor said its conclusion on Jaykay Enterprises' unaudited standalone results was not modified in respect of Neumesh Labs, while drawing attention to the subsidiary's financial position and the absence of an impairment provision.
How large is Jaykay Enterprises' exposure to Neumesh?
Jaykay Enterprises' aggregate exposure to Neumesh Labs was Rs 22.32 crore at September 30, 2026, including Rs 3.60 crore of interest receivable. The filing groups the balance across investment, loans and interest receivable, but does not state separate amounts for the investment and loan components. Management's recoverability assessment therefore covers the stated Rs 22.32 crore total.
Neumesh Labs' negative net worth was Rs 35.3411 crore at September 30, 2026, while its current liabilities exceeded its current assets by Rs 36.3141 crore. These measures differ from Jaykay Enterprises' Rs 22.32 crore carrying exposure, but they describe the subsidiary's financial position at the same reporting date.
What does Neumesh Labs' September 2026 financial position show?
Neumesh Labs had fully eroded its net worth to negative Rs 35.3411 crore as of September 30, 2026, and current liabilities exceeded current assets by Rs 36.3141 crore. Jaykay Enterprises said the subsidiary nevertheless prepared its financial statements on a going-concern basis, alongside management's recoverability assessment of the investment, loans and interest receivable.
Neumesh Labs held no property, plant and equipment, or PPE, for its business activities at September 30, 2026. The filing pairs that disclosure with the temporary pause in commercial operations and management's plan to formulate a digital-services business plan to revive operations.
Jaykay Enterprises did not disclose an expected recovery amount, a timetable for recovery or the detailed proposed recovery strategies supporting the Rs 22.32 crore carrying value. It also did not disclose a launch date, revenue target, funding requirement or customer contract for Neumesh Labs' proposed digital-services business plan as of September 30, 2026.
Got a follow-up? Ask IRIS
How did Jaykay Enterprises' September quarter compare with earlier periods?
Jaykay Enterprises reported standalone operating income of Rs 8.7014 crore for the quarter ended September 30, 2026, compared with Rs 1.6168 crore in the June 2026 quarter and Rs 72.60 lakh in the September 2025 quarter. Total revenue was Rs 9.9636 crore, against Rs 2.8751 crore in June 2026 and Rs 3.1287 crore a year earlier, including Rs 1.2622 crore of other income in the latest quarter.
Standalone net profit was Rs 49.42 lakh for the September 2026 quarter, compared with Rs 1.26 lakh in the June 2026 quarter and Rs 1.0074 crore in the September 2025 quarter. Profit before tax was Rs 59.66 lakh in September 2026, versus Rs 15.42 lakh in June 2026 and Rs 97.19 lakh a year earlier. The figures show a quarter-on-quarter increase in profit but a year-on-year decline.
For the half year ended September 30, 2026, Jaykay Enterprises recorded operating income of Rs 10.3182 crore, compared with Rs 1.2335 crore in the corresponding half year of 2025. Half-year total revenue was Rs 12.8387 crore, versus Rs 23.4559 crore a year earlier, when other income included Rs 18.3992 crore from sale of shares. Net profit was Rs 50.68 lakh, compared with Rs 16.3313 crore in the prior-year half year.
Jaykay Enterprises' board approved the September 2026 standalone results on November 13, 2026 after audit committee review. The company disclosed no provision for credit impairment or diminution in the value of the Neumesh Labs investment, loans and interest receivable in the quarter or half-year figures, so the reported Rs 49.42 lakh quarterly net profit contains no such charge.
Conclusion
Jaykay Enterprises retained Rs 22.32 crore linked to Neumesh Labs despite the subsidiary's paused operations, lack of PPE, negative Rs 35.3411 crore net worth and Rs 36.3141 crore excess of current liabilities over current assets at September 30, 2026. Management's stated recoverability view, rather than a recognised impairment or diminution charge, determined the accounting treatment in the reported standalone results.
The disclosed matter to watch is Neumesh Labs' formulation of its digital-services business plan and intended revival of commercial operations. Jaykay Enterprises had not disclosed a target date, funding plan, customer contract or recovery amount as of September 30, 2026, leaving future financial statements to show whether the plan progresses or prompts a reassessment of carrying values.


